PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 30, 2024Clinical Cancer Research28 citationsOpen Access

Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1/2 and a scar-based HRD signature in real-world practice

View Full Paper
DRDebra L. RichardsonJQJúlia C.F. QuintanilhaNDNatalie Danziger

Key Points

Key points are not available for this paper at this time.

Abstract

The purpose of the study was to compare the effectiveness of PARP inhibitor maintenance therapy (mPARPi) in real-world practice by biomarker status BRCA1/2 alterations (BRCAalt) and a homologous recombination deficiency signature (HRDsig) in advanced ovarian cancer.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Richardson et al. (2024) studied this question.

synapsesocial.com/papers/68e5e6efb6db64358757b878https://doi.org/10.1158/1078-0432.ccr-24-1225
Ask AI
Helpful
Bookmark
Share
View Full Paper